Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis

Rheumatology International

Volumn 33, Issue 6, 2013, Pages 1415-1418

  Bes, Cemal ^a   Yazici, Ayten ^b   Soy, Mehmet ^c  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Sakarya Education and Research Hospital ^*  (Turkey)

^c Hisar Intercontinental Hospital   (Turkey)

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor alpha; Hemoglobin

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; HEMOGLOBIN; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DEMOGRAPHY; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878728157     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2539-5     Document Type: Article

References (15)

1. Haywood KL, Garratt AM, Dawes PT (2005) Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 44(5):577-586
2. Maksymowcyh WP (2003) Spondyloarthropathies: ankylosing spondylitis. In: Hochberg H, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, vol 3. Elsevier Lmt, Phildelphia, pp 1183-1192
3. Rosenbaum JT (1989) Characterization of uveitis associated with spondyloarthritis. J Rheumatol 16(6):792-796
4. Crowley JJ, Donnelly SM, Tobin M, FitzGerald O, Bresnihan B, Maurer BJ, Quigley PJ (1993) Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. Am J Cardiol 71(15):1337-1340
5. Reveille J (2008) Clinical features of ankylosing spondylitis. In: Hochberg M, Silman A, Smolen JS (eds) Rheumatology, vol 4. St. Louis, Mosby, pp 1109-1114
6. Levine DS, Forbat SM, Saifuddin A (2004) MRI of the axial skeletal manifestations of ankylosing spondylitis. Clin Radiol 59(5):400-413
7. Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032-1036
8. Paulus HE (1988) FDA arthritis advisory committee: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum 31:1450-1451
9. Roy CN, Andrews NC (2005) Anemia of inflammation: the hepcidin link. Curr Opin Hematol 12:107-111
10. Braun J, Baraliakos X (2009) Treatment of ankylosing spondylitis and other spondyloarthritidies. Current Opinion Rheumatol 21(4):324-334
11. van den Berg R, van der Heijde DM. How should we diagnose spondyloarthritis according to the ASAS classification criteria: a guide for practicing physicians
12. Guignard S, Gossec L, Salliot C, Ruyssen A, Luc M, Duclos M et al (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65(12):1631-1634
13. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD et al (2001) Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5):1088-1094
14. Grigorakaki C, Morceau F, Chateauvieux S, Dicato M (2011) Tumor necrosis factor alpha- mediated inhibition of erythropoiesis involves GATA-1/GATA-2 balance impairment and PU.1 over-expression. Chem Pharmacol 82(2):156-166
15. Silva LC, Ortigosa LC, Benard G (2010) Anti-TNF-α agents in the treatment of immune- mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2(6):817-833